Asia Pacific Stem Cell Therapy Market Size, Demand, Share, Revenue, Key Players, Growth, and Forecast 2023 to – openPR

Astute Analytica's recently published report on the Asia Pacific Stem Cell Therapy Market offers the latest data and determines growth prospects and challenges. A tool for evaluating the potential for new goods and services is the constraints and opportunity analysis. This aids businesses in locating and forecasting market opportunities.

Request Of this Sample Report Here- https://www.astuteanalytica.com/request-sample/asia-pacific-stem-cell-therapy-market

The study also contains a compilation of qualitative and quantitative evaluations made by subject-matter experts in their fields as well as representatives from various industries found all along the supply chain.

The Asia Pacific stem cell therapy market is poised for substantial growth in the coming years, with a projected compound annual growth rate (CAGR) of 10.29% between 2023 and 2031. This growth is expected to drive the market value up to US$ 3,420.05 Mn by 2031, following a successful revenue performance of US$ 1,453.61 Mn in 2022.

The paper discusses further findings that researchers made based on the comprehensive data and also offers information on the state of the market. The paper discusses kinds and applications based on various nations and important locations. The market's most active companies are described in detail with regard to attributes like corporate portfolio, business strategy, financial overview, recent developments, and industry share.

Leading Companies

AlloSourceAnterogen Co. Ltd.Arce TherapeuticsAstellas Pharma IncBiogend TherapeuticsBiorestorative Therapies Inc.Brainstorm Cell Limited.Cellular Biomedicine GroupCORESTEMFujifilm Holding CorporationHolostem Terapie Avanzate SrlJCR Pharmaceuticals Co. Ltd.Kangstem BiotechMEDIPOST Co. Ltd.Mesoblast LtdPersonalized Stem CellsPELL Biotech Co., Ltd.Pluristem Inc.RTI SurgicalSartorius AGSewon CellontechSmith+NephewSTEMPEUTICS RESEARCH PVT LTD.Takeda Pharmaceutical Company LimitedVericel CorpOther Prominent PlayersMore Full Report Here- https://www.astuteanalytica.com/industry-report/asia-pacific-stem-cell-therapy-market

We continuously monitor the direct impact COVID-19 (Update Omicron mutations study) has on the market, in addition to the indirect influence of related industries. The report will contain the observations.

The geographical regions are divided into several major categories for production, consumption, revenue (in US dollars), and market share in this analysis. We'll discuss the predicted growth of the market in this region between 2021 and 2031.

Segmentation Overview

The Asia Pacific stem cell therapy market is segmented based on therapy type, product, cell source, technology, application and end user.

By Therapy Type segmented, the Asia Pacific stem cell therapy market is sub-segmented into:

Autologous Stem Cell TherapyAllogeneic Stem Cell TherapyBy Product segment, the Asia Pacific stem cell therapy market is sub-segmented into:

Adult Stem Cells (ASCs)Human Embryonic Stem Cells (HESCs)Induced Pluripotent Stem Cells (iPSCs)Very Small Embryonic Like Stem CellsBy Cell source segment, the Asia Pacific stem cell therapy market is sub-segmented into:

Adipose tissue derived MSCsBone marrow derived MSCsPlacental/umbilical cord derived MSCsOther Cell SourcesBy technology segment, the Asia Pacific stem cell therapy market is sub-segmented into:

Cell AcquisitionCell ProductionCryopreservationExpansion and Sub-CultureBy application segment, the Asia Pacific stem cell therapy market is sub-segmented into:

Musculoskeletal DisordersWounds and InjuriesAcute Graft-Versus-Host Disease (AGVHD)SurgeriesGastrointestinal DiseasesCardiovascular DiseasesInflammatory & Autoimmune DiseasesNeurological DisordersOthersBy end user segment, the Asia Pacific stem cell therapy market is sub-segmented into:

HospitalsResearch institutesSurgical institutesOthersBy country, the Asia Pacific stem cell therapy market is sub-segmented into:

ChinaIndiaJapanAustralia & New ZealandASEANTaiwanSouth KoreaRest of Asia Pacific

Access Sample Report Here- https://www.astuteanalytica.com/request-sample/asia-pacific-stem-cell-therapy-market

About Astute Analytica:

Astute Analytica is a global analytics and advisory company that has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in-depth, and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the globe.

They are able to make well-calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment-wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of the best cost-effective, value-added package from us, should you decide to engage with us.

Get in touch with us:

Phone number: +18884296757

Email: sales@astuteanalytica.com

Visit our website: https://www.astuteanalytica.com/

This release was published on openPR.

Read the original here:
Asia Pacific Stem Cell Therapy Market Size, Demand, Share, Revenue, Key Players, Growth, and Forecast 2023 to - openPR

With A CAGR of 4.9%, Research Antibodies Market Size Worth USD 2.17 Billion By 2030 | Emergen Research – EIN News

Research Antibodies Market Trends An increase in research and development (R&D) activities related to the fields of neurobiology

Emergen Research

The global research antibodies market is projected to be worth USD 5,325.8 Million by 2027, according to a current analysis by Emergen Research. The market for research antibodies is witnessing a high demand due to its growing application in neurobiology, infectious diseases, oncology, stem cells, and immunology, among others. Increased investments in research in the field of stem cells is also a crucial growth factor of the Research Antibodies market.

To Get Free Sample PDF Copy of This Report

https://www.emergenresearch.com/request-sample/192

Research Antibodies Market, By Antibody Type (Monoclonal and Polyclonal), By Antibody Type (Primary Antibodies and Secondary Antibodies), By Application, By Technology, By End-use, and By Region Forecast to 2030. An increase in research and development (R&D) activities related to the fields of neurobiology, oncology and stem cell research, the increasing incidence of cancer and infectious diseases, and the growing demand from the biopharmaceutical industry for these antibiotics are the main drivers of the market. increase the revenue. Research antibodies are antibodies that can bind to specific molecules, which are used as basic detection tools needed in scientific research and are also important tools for studying protein function in cell.

Key Players Included in this report are:

Lonza Group, Becton, Dickinson, and Company, Agilent Technologies, Abcam PLC, PerkinElmer Inc., Bio-Rad Laboratories, Merck Millipore, F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Cell Signaling Technology Inc.

What can be explored with the Research Antibodies Market Study?

Gain Market Understanding

Identify Growth Opportunities

Analyze and Measure the Global Research Antibodies Market by Identifying Investment across various Industry Verticals

Understand the Trends that will drive Future Changes in Research Antibodies Market

Understand the Competitive Scenarios

Track Right Markets

Identify the Right Verticals

Quick Buy Research Antibodies Market

https://www.emergenresearch.com/select-license/192

Some Key Highlights from the Report

The research antibodies market has been divided into hospitals, dental offices, and other end-uses. Over the projected period, it is anticipated that the dental clinics segment will contribute the most to total revenue. They meet a variety of client needs and offer the necessary knowledge, along with a vast array of technologically cutting-edge tools and supplies, to perform any orthodontic procedure. Better patient reimbursement dental policies are available at dental clinics. Furthermore, the significant market share of dental clinics is caused by an increase in orthodontists' private practises. Some major companies in the global research antibodies market report include Merck KGaA, Johnson & Johnson Services, Inc., Eli Lilly and Company., Bio-Rad Laboratories, Inc., Cell Signalling Technology, Inc., PerkinElmer Inc., ROCKLAND IMMUNOCHEMICALS, INC., Novartis AG, BD, and Abcam plc. Market Segmentation Analysis

Players can concentrate on high-growth regions and, if necessary, modify their business plan according to the research report. The Research Antibodies Market is divided into a variety of categories, uses, and geographical areas. Players gain from the report's regional segmentation research since it offers pertinent data and insights into important geographic marketplaces.

Antibody Type Outlook (Revenue, USD Million; 2017-2027) Monoclonal Polyclonal Product Outlook (Revenue, USD Million; 2017-2027) Primary Antibodies Secondary Antibodies COVID-19 Impact Analysis

The post-COVID-19 phase has undergone substantial change, and Research Antibodies Market research highlights the opportunities and difficulties that still exist. This study report thoroughly examines the effects of the COVID-19 pandemic on the global economy and post-pandemic market behaviour.

Ask for Customization

https://www.emergenresearch.com/request-for-customization/192

Regional Outlook

We carefully examined each division, regional classification, national study, and subject-specific data set during the market research. This Research Antibodies Market research report's goal is to look at growth patterns, promising futures, important obstacles, and expected results. Information on significant market participants, strategic alliances, plans, new product launches, and joint ventures are all included in the research.

Research Methodology

Emergen Research follows a cohesive methodology to reduce the residual errors to a minimum level by refining the scope, validating through primary insights, and nurturing the in-house database on a regular basis. A dynamic model is formulated to capture the regular fluctuations in the market and thereby, being updated with any shifts in the market dynamics.

PRIMARY RESEARCH MODEL

Post conglomeration of the data obtained through secondary research; a validation process is initiated to verify the numbers or figures. This process is usually performed by having a detailed discussion with the industry experts. Discussions with the subject matter experts were conducted to obtain quantitative and qualitative information and validate our market research findings.

Key Reasons to Purchase Research Antibodies Market Report

The reader will be in a position to comprehend and react to marketing strategies like using strengths and conducting a SWOT analysis.

The research looks into the dynamics of the target market and how the conflict between Russia and Ukraine has affected it.

Look Over transcripts provided by Emergen Research

Artificial Neural Network Market

https://usahealthnewswire.blogspot.com/2023/04/artificial-neural-network-market-global.html

Nebulizers Market

https://usahealthnewswire.blogspot.com/2023/04/nebulizers-market-size-share-price.html

Routing Market

https://usahealthnewswire.blogspot.com/2023/04/routing-market-global-industry-size.html

Industrial Robotics Market

https://usahealthnewswire.blogspot.com/2023/04/industrial-robotics-market-global.html

Thank you for reading our report. Please get in touch with us if you have any query regarding the report or its customization. Our team will ensure the report is best suited to your needs.

About Us:

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Eric LeeEmergen Research+91 90210 91709sales@emergenresearch.comVisit us on social media:FacebookTwitterLinkedIn

Read this article:
With A CAGR of 4.9%, Research Antibodies Market Size Worth USD 2.17 Billion By 2030 | Emergen Research - EIN News

EW GROUP SHINES AT 12TH A4M SYMPOSIUM 2023 & – InvestorsObserver

BANGKOK , April 11, 2023 /PRNewswire/ -- European Wellness Biomedical Group (EW Group) made a successful showing at an exclusive event, the 12 th A4M Symposium 2023, which was held in Centara, Bangkok , 16 th -19 th February 2023 .

The two-day A4M Symposium, commenced with a welcome ceremony featuring Dr. Manus Potaporn (Deputy Director General of Medical Services Department, Thailand ) as a Guest of Honour, hosted by Prof. Dr. Mike Chan (A4M Thailand President), Dr. Jakkriss Bumisawasdi (A4M Thailand Honorary President), and Dr. Robert Goldman (A4M Founder).

On February 19 , European Wellness Academie (EWA), a non-profitable educational arm of EW Group, brought an exclusive workshop, "All-On Bioregen Optimization," to explore the world of anti-aging and regenerative medicine, featured some of the world's leading anti-aging experts.

Prof. Dr. Mike Chan , presented his two topics, "The Application of Regenerative Precursor Stem Cells, Peptides & Exosomes in Precision Medicine" and "Phyto-Myco-based Nano Organo Peptides: A New Trend in Precision Medicine."

"Precision Medicine in Age Reversal," which brought together the anti-aging and wellness industries on a single platform to achieve Precision Medicine's goals, which are patient-centred, may divide patients into subgroups based on their illness vulnerability, prognosis, or response to a specific treatment. It is devised and administered after comprehensive diagnostics utilizing Panomic Analysis and System Biology to analyse the patient's state at a molecular level and apply targeted therapies to address illness progression.

Anti-aging medicine aims to improve human ageing and maximize physical and mental well-being. Scientific data and medical journals supported the model's focus on Advanced Clinical Preventive and Regenerative Medicine.

The involvement of the healthcare and wellness industries will have a significant influence on the anti-aging sector for many years to come. Yet, by fact these sectors worked together to improve the quality of life for individuals and will contribute to defining the very future of modern medicine.

European Wellness Biomedical Group

An award-winning European group, most renowned for its pioneering development in organ-specific precursor (progenitor) stem cell therapeutics, biological and synthetic peptides, biological regenerative medicine, immunotherapies, and nutraceutical and cosmeceuticals.

EW Group's multinational business divisions include research and developments, bio-manufacturing, biomedical academies, hospital and wellness centres and nutraceutical product distribution across 80 countries worldwide. EW Group also owns and operates a growing network of internationally accredited Hospital and Medical Centres specializing in Regenerative Bio-Medicine and luxury Wellness Centres globally. EW Group is headquartered in Germany and Malaysia ( Asia Pacific ) with research vested in Germany , Switzerland , Czech Republic and United Kingdom .

Home

Media Contact: Ferellica Anne Martin +6088 448 989 (Ext: 337) media@european-wellness.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/ew-group-shines-at-12th-a4m-symposium-2023--all-on-bioregen-optimization-workshop-301796266.html

SOURCE European Wellness Biomedical Group

Continue reading here:
EW GROUP SHINES AT 12TH A4M SYMPOSIUM 2023 & - InvestorsObserver

Jasper Therapeutics Appoints David Hinds as Senior Vice President … – GlobeNewswire

REDWOOD CITY, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of David Hinds, as the Companys Senior Vice President, Development Operations.

We are pleased to welcome David to our team. His outstanding track record in setting strategic directions for clinical research and operations will allow us to effectively advance our development programs for briquilimab, said Ronald Martell, President and Chief Executive Officer of Jasper. As we navigate through a critical phase in our advancement of this promising asset, Davids leadership will be instrumental in rapidly progressing briquilimab in chronic spontaneous urticaria and initiating chronic lower-risk MDS study, all while maintaining momentum in the SCID, Fanconi Anemia, and sickle cell disease transplant studies recruitment.

Mr. Hinds brings more than 25 years of experience in operations and clinical program development across multiple therapeutic areas, all phases of development, and all regions of the world. Throughout his career, Mr. Hinds held a number of leadership roles, most recently as Vice President and General Partner at ICON plc, the worlds leading clinical research organization. Previously he served as Vice President, Clinical Operations at PellePharm and Tioma Therapeutics. He also led the clinical development and operations strategy at Alios Biopharma, Takeda, Clinipace, Exelixis, Kai Pharmaceuticals, Genentech, Genitope Corporation, and Intermune. He directly contributed to the success of global products including Rituxan, Adcetris, Velcade, Truvada, Orbactiv, Pirfenidone, and Celebrex. Mr. Hinds earned a Masters of Business Administration from Moore School of Business, University of South Carolina, and a Bachelor of Science in Biology at The Citadel The Military College of South Carolina.

I am thrilled to join the Jasper team at such an exciting time as the Company expands the development of briquilimab into chronic mast cell diseases and advances its novel conditioning approach for stem cell transplant, said Mr. Hinds. I look forward to contributing to the Jasper team by leveraging all the hard work that has been accomplished to date and executing on near-term clinical milestones.

About Jasper

Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA) and severe combined immunodeficiency (SCID). To date, briquilimab has a demonstrated efficacy and safety profile in over 130 dosed subjects and healthy volunteers, with clinical outcomes as a conditioning agent in SCID, acute myeloid leukemia (AML), MDS, FA, and SCD. In addition, briquilimab is being advanced as a transformational non-genotoxic conditioning agent for gene therapy. For more information, please visit us atwww.jaspertherapeutics.com.

Forward-Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as believe, may, will, estimate, continue, anticipate, intend, expect, should, would, plan, predict, potential, seem, seek, future, outlook and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimabs potential, including with respect to its potential to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes as well as novel stem cell transplant conditioning regimes, its potential to address a variety of patient populations by targeting c-Kit expressed on stem cells and mast cells and its efficacy and safety profile, pathways to market, the expansion of briquilimab development, Jaspers expectations regarding the timing of clinical trials and recruitment for clinical trials and Jaspers expectations regarding its cash and cash equivalents and planned operating and capital expenditures. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jaspers product candidates may not be beneficial to patients or successfully commercialized; patients willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jaspers business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jaspers business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics, including the ongoing COVID-19 pandemic; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jaspers filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2022. If any of these risks materialize or Jaspers assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jaspers assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Contacts:

John Mullaly (investors)LifeSci Advisors617-429-3548jmullaly@lifesciadvisors.com

Jeet Mahal (investors)Jasper Therapeutics650-549-1403jmahal@jaspertherapeutics.com

Lauren Barbiero (media)Real Chemistry646-564-2156lbarbiero@realchemistry.com

Read more:
Jasper Therapeutics Appoints David Hinds as Senior Vice President ... - GlobeNewswire

Simultaneous diagnosis and treatment of cancer now possible – Science Daily

Cancer is not incurable anymore. Nevertheless, according to statistics released by Statistics Korea last year, cancer remained the primary cause of mortality in Korea in 2021. This highlights the ongoing struggle against cancer, which demands effective prevention measures as well as timely diagnosis and prompt intervention through effective treatment. However, the question remains whether it is feasible to provide treatment promptly upon diagnosis.

A POSTECH research team led by Professor Young Tae Chang (Department of Chemistry) and Research Professor Nam-Young Kang (Department of Convergence IT Engineering) collaborated with researchers at A*STAR in Singapore to determine the ability of fluorescent probe for tumor-initiating cell yellow (TiY) to stain the cells responsible for tumor growth and simultaneously suppress the growth of those cells. The empirical data of the research was published in the journal Theranostics, which covers treatment, diagnosis, and personalized medicine.

In their previous study, the research team developed fluorescent probe TiY with the ability to selectively identify and detect tumor-initiating cells (TICs), much like a fluorescent highlighter. Building upon this accomplishment, the team has conducted research aimed at exploring the potential of TiY for cancer treatment.

In the present study, the team observed changes in cancer stem cells in response to different concentrations of TiY. The team obtained cancer stem cells from patients with lung cancer and transplanted them into mice for experimental purposes. In order to evaluate the therapeutic effects of TiY staining, the team gradually increased the dose of TiY administered to the mice via intravenous injection in their tests.

When exposed to a low concentration, TiY has been demonstrated to have the ability to stain cancer stem cells. However, as the concentration of TiY increases, it exhibits the remarkable ability to effectively inhibit the growth of cancer stem cells, leading to their substantial destruction. This selective targeting and treatment are made possible by the mechanism of TiY molecules, which have the capacity to selectively bind themselves to vimentin, a muscle-specific protein that is a component of the cytoskeleton of cancer stem cells, thus allowing TiY to specifically target and inhibit these cells of growth.

Current cancer treatments often fail to achieve complete tumor removal, as cancer cells can be metastasized to other organs or recur. Given the challenge, TiY presents a promising approach to cancer treatment as it can facilitate both diagnosis and treatment in a single step

This study was conducted with the support from the Ministry of Science and ICT, the Ministry of Education, the Mid-career Researcher Program of the National Research Foundation of Korea, the Institute of Basic Science, and the NMRC in Singapore.

More here:
Simultaneous diagnosis and treatment of cancer now possible - Science Daily

Stem Cell Therapy for Hips Shaw Local – The Herald-News

Stem cell therapy is a rapidly growing area of medical research and practice. Stem cells are master cells that can develop into any other cell type in the body. Stem cells show great promise in treating various illnesses and injuries, including those involving the hip. Numerous studies have demonstrated remarkable success rates when using stem cell therapy to treat hip-related conditions.

Here are three things to know about stem cell therapy for hips:

What it is:

Stem cell therapy uses amniotic fluid or umbilical cord and placental derived stem cells to regrow healthy tissue in areas damaged from injury or disease. In the case of hip-related issues, stem cells can regenerate cartilage and other soft tissue, such as ligaments and tendons, allowing for improved mobility and range of motion.

Benefits:

Stem cell therapy is a procedure that offers quick recovery times compared to traditional treatments like surgery or joint replacement. The risk associated with Regenerative Medicine is low. There are no incisions or sutures, and while we suggest you take it easy the day of and after the procedure, there is essentially no recovery time.

Procedure & Results:

During stem cell therapy, the harvested sample is injected directly into the area of concern. Multiple injections may be necessary to achieve desired results depending on the extent of damage or injury. Generally, patients can expect improved mobility and range of motion after undergoing stem cell therapy for hips. But above all, many can take the surgical option off the table.

Stem cell therapy for hips is an exciting area of medical research and treatment that offers the potential for a speedy recovery with minimal risk of complications. Those considering stem cell therapy should discuss their options to determine if it is right for them.

At Chicago Stem Cell Therapy & Pain Management Institute, we maximize our patients potential through the latest and highest quality stem cell treatments. Contact Dr. Anwar at 815-412-6187 today and discover how this revolutionary treatment can improve your life.

Chicago Stem Cell Therapy & Pain Management Institute

10181 W Lincoln Hwy

Frankfort, IL 60423

http://www.ChicagoStemCellTherapy.com

chicago stem cell therapy & pain management institute sponsored logo 2022

[sponsored] Chicago Stem Cell Therapy & Pain Management Institute [sponsored] Chicago Stem Cell Therapy & Pain Management Institute

Read the original post:
Stem Cell Therapy for Hips Shaw Local - The Herald-News

Inland Empire stem-cell therapy gets $2.9 million booster – UC Riverside

A new UC Riverside training program will help undergraduates transition into regenerative medicine careers, infusing the Inland Empire wraith expertise in cutting-edge trauma and disease treatments.

Guadalupe Ruiz,RAMP diversity and outreach director, left, and Huinan Hannah Liu, bioengineering professor and RAMP principal investigator. (Stan Lim/UCR)

The Research Training and Mentorship Program to Inspire Diverse Undergraduates toward Regenerative Medicine Careers, or RAMP, has received $2.9 million to work with multiple groups of students over the next five years. The grant comes from the California Institute for Regenerative Medicine, the states stem cell agency.

The overall goal of the program is to develop therapies for cells and tissues damaged by injury, trauma, or disease, including brain cells. Laboratory work will include tissue engineering but also research into techniques where the body uses its own biological systems, sometimes with help of engineered materials to rebuild tissues and organs.

UCR already had parts of a stem-cell career training pipeline in place. The university hosts STRIDE, a program offering local high school students opportunities to participate in laboratory research projects. In addition, the TRANSCEND program, directed by UCR molecular biology professor Prue Talbot, helps increase the number and diversity of Ph.D. and postdoctoral scientists trained in stem cell biology.

The missing link was undergraduates, said Huinan Hannah Liu, UCR bioengineering professor and RAMP principal investigator. RAMP is a linker molecule between those two programs.Interested undergrads are encouraged to apply.

Liu got involved with the program because her laboratory works on ways to improve cellular nutrient delivery and waste transport. A lot of metabolic waste in a cell impedes regeneration, Liu said. Nothing thrives in an environment full of waste.

Sometimes called the body's master cells, stem cells develop into blood, brain, bones, and all of the body's organs. They have the potential to repair, restore, replace, and regenerate cells. (luismmolina/iStock/Getty)

Her focus mirrors the first of three sub-specialties from which RAMP students will be able to choose. Faculty from UCRs Marlan and Rosemary Bourns College of Engineering will work with students to engineer materials that serve as scaffolds for growing cells and tissues.

Students can also choose to work with faculty from the College of Natural and Agricultural Sciences, who have expertise in cell biology. They understand the biological mechanisms behind tissue development, and the pathology of different disease stages, Liu said. Their collaboration with engineering faculty will be critical.

Faculty from UCRs School of Medicine will also work with students on ways to differentiate stem cells toward various cell types, and research the mechanisms of how cells and tissues function in the body. They can determine, for example, whether the body will accept an engineered cell, Liu said.

Moving forward, Liu is hopeful that RAMP will attract more clinical faculty, who can help do studies to test whether engineered materials, cells and tissues are safe before translating the work to human subjects.

Another key component of the program will be reaching out to patients and local communities to make them aware of new treatment options available to them. As they see the need in our area, Im hopeful these students will remain long term and help heal our diverse, underserved Inland Empire communities, Liu said.

(Cover image: stem cells: luismmolina/iStock/Getty)

Go here to see the original:
Inland Empire stem-cell therapy gets $2.9 million booster - UC Riverside

Mount Sinai Awarded Prestigious $1.3 Million Grant to Expand … – Mount Sinai

The Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai will expand its research training program in skin biology with support from a five-year, $1.3 million T32 grant from the National Institutes of Health (NIH) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).

The research training program in Systems Skin Biology will take a multidisciplinary approach in teaching scientists to holistically understand human physiology, health, and disease. As a recognized leader in research for skin biology and skin diseases, Mount Sinai will also become an incubator for future biomedical leaders in the field as a result of this program.

Traditional skin biology often focuses on the most obvious cells of the skin, keratinocytes, which form the structure of the epidermis and are essential for skin repair. The Systems Skin Biology program will take an interconnected approach based on the premise that neurons, immune cells, and blood vessels are just as much skin biology as traditional skin cells. Mount Sinai researchers have previously discovered new treatments for itch by studying the intersection of nerves and immune cells, and believe future studies through the Systems Skin Biology program will uncover understandings about wound repair, cancer, hair loss, vitiligo, and acne.

Science and medicine are rapidly evolving, and thus, the training itself must adapt, said co-Principal Investigator Brian S. Kim, MD, MTR, FAAD, Vice Chair of Research and Director of the Mark Lebwohl Center for Neuroinflammation and Sensation at Icahn Mount Sinai. This T32 program is truly unique in that it moves away from focusing on only one discipline, but embraces interdisciplinary training across two traditionally disparate fieldssuch as neuroscience and immunologyby using the skin and associated diseases as a model paradigm.

Dr. Kim, a renowned physician-researcher in chronic itch and inflammatory skin conditions, said the grant (number 1T32AR082315-01) will initially fund two predoctoral fellows or physician-scientists and two postdoctoral fellows or physician-scientists. It will facilitate the training of students toward PhD and/or MD/PhD degrees in intersectional skin biology, as well as training scientists and clinicians with advanced degrees to become independently funded principal investigators. In addition to dermatology, the research training program in Systems Skin Biology will include expertise drawn from across the Health System, including skin biology, immunology, neuroscience, epithelial biology, translational medicine, and stem cell biology.

This training grant will be particularly helpful for pre- and postdoctoral fellows and dermatology residents interested in bringing a new angle and new approaches to skin research, said co-Principal Investigator Sarah E. Millar, PhD, Director of the Black Family Stem Cell Institute and Senior Associate Dean for Basic Research at Icahn Mount Sinai. After training in diverse labs across Mount Sinais campus, they will be able to apply those new skills to uncover novel mechanisms in skin biology and diseases.

This T32 program is one of many steps toward our Department becoming the epicenter of innovation and a world leader in dermatology, as well as in training the future leaders and key opinion thought leaders in dermatology, said Emma Guttman-Yassky, MD, PhD, Waldman Professor of Dermatology and Immunology at Icahn Mount Sinai and Chair of Dermatology at the Mount Sinai Health System. In addition to bringing recognition of the breadth of institutional excellence in cutaneous diseases and skin biology at Mount Sinai, this training program will have an indelible impact on the future of dermatology and dermatology research for decades to come.

Mount Sinai continues to be a leader in the field of skin biology throughout New York City and the tri-state region. In 2021, the Health System established a Skin Biology and Diseases Resource-based Centerthen one of only six nationwide supported by a NIAMS grant. The Center uses technical innovations, high-end infrastructure, and computing power available at Mount Sinai to advance and support skin research; it also embeds experts in gene editing, genomics, and bioinformatics within skin research labs to break down interdisciplinary communication barriers.

About the Icahn School of Medicine at Mount Sinai

The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the eight member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to a large and diverse patient population.

Ranked No. 14 nationwide in National Institutes of Health funding and in the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges, Icahn Mount Sinai has a talented, productive, and successful faculty. More than 3,000 full-time scientists, educators, and clinicians work within and across 34 academic departments and 44 multidisciplinary institutes, a structure that facilitates tremendous collaboration and synergy. Our emphasis on translational research and therapeutics is evident in such diverse areas as genomics/big data, virology, neuroscience, cardiology, geriatrics, and gastrointestinal and liver diseases.

Icahn Mount Sinai offers highly competitive MD, PhD, and masters degree programs, with current enrollment of approximately 1,300 students. It has the largest graduate medical education program in the country, with more than 2,600 clinical residents and fellows training throughout the Health System. In addition, more than 535 postdoctoral research fellows are in training within the Health System.

A culture of innovation and discovery permeates every Icahn Mount Sinai program. Mount Sinais technology transfer office, one of the largest in the country, partners with faculty and trainees to pursue optimal commercialization of intellectual property to ensure that Mount Sinai discoveries and innovations translate into health care products and services that benefit the public.

Icahn Mount Sinais commitment to breakthrough science and clinical care is enhanced by academic affiliations that supplement and complement the Schools programs. Through Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai. Additionally, MSIP develops research partnerships with industry leaders such as Merck & Co., AstraZeneca, Novo Nordisk, and others.

The Icahn School of Medicine at Mount Sinai is located in New York City on the border between the Upper East Side and East Harlem, and classroom teaching takes place on a campus facing Central Park. Icahn Mount Sinais location offers many opportunities to interact with and care for diverse communities. Learning extends well beyond the borders of our physical campus, to the eight hospitals of the Mount Sinai Health System, our academic affiliates, and globally.

-------------------------------------------------------

* Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Beth Israel; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai.

Read this article:
Mount Sinai Awarded Prestigious $1.3 Million Grant to Expand ... - Mount Sinai

Global Cell Culture Market Report 2023: Government Support and Funding for Cell-Based Research Bolsters Growth – Yahoo Eurosport UK

Company Logo

Global Cell Culture Market

Global Cell Culture Market

Dublin, April 04, 2023 (GLOBE NEWSWIRE) -- The "Global Cell Culture Market by Product (Consumables (Media, Sera, Reagent), Vessel (Roller bottle, Cell Factory), Equipment (Bioreactor, Centrifuges, Incubators)), Application (mAbs, Vaccines, Diagnostics, Tissue Engineering), End User - Forecasts to 2028" report has been added to ResearchAndMarkets.com's offering.

The global cell culture market is projected to reach USD 51.3 billion by 2028 from USD 27.9 billion in 2023, at a CAGR of 12.9% during the forecast period of 2023 to 2028. The growth of this market is majorly driven by the adoption of single-use technologies, growing focus on product development, growing popularity of monoclonal antibodies, and growth in cell and gene therapies and stem cell research. On the other hand, the high cost of cell biology research is restraining the growth of this market.

The supporting equipment sub-segment accounted for the largest share of the equipment segment during the forecast period

By product, the supporting equipment sub-segment accounted for the largest share of the equipment segment. Cell culture supporting equipment includes filtration systems, cell counters, carbon dioxide incubators, centrifuges, autoclaves, microscopes, biosafety cabinets, and other supporting equipment such as pipetting aids, pipettes, cell inserts, cell scrapers, cell lifters, cell spreaders, pH meters, shakers, flow cytometers, and water baths. These equipment play a vital role in maintaining optimum cell culture conditions. The increasing focus on cancer research, cell-based research and stem-cell research coupled with the rising need to meet the GMP standards and regulations is expected to fuel the segment market growth.

Europe: The second largest region in the cell culture market

Factors such as the increasing incidence of chronic diseases, rising government investments in life sciences, and increasing focus on stem cell research and regenerative medicine are driving the growth of the cell culture market in Europe. Moreover, several conferences, symposia, seminars, trade fairs, annual events, and workshops are being organized in Europe to create awareness of cell culture products.

Story continues

Market Dynamics

Drivers

Government Support and Funding for Cell-Based Research

Emerging Cell Culture Technologies for Cell-Based Vaccines

Growing Popularity of Monoclonal Antibodies

Adoption of Single-Use Technologies

Growing Focus on Product Development

Growth in Cell and Gene Therapies and Stem Cell Research

Incidence of Infectious Diseases

Restraints

Opportunities

Demand for 3D Over 2D Cell Cultures

Growth Hotspots in Emerging Economies

Challenges

Disposal of Plastic Consumables

Key Attributes:

Report Attribute

Details

No. of Pages

692

Forecast Period

2022 - 2027

Estimated Market Value (USD) in 2022

$27.9 Billion

Forecasted Market Value (USD) by 2027

$51.3 Billion

Compound Annual Growth Rate

12.9%

Regions Covered

Global

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Cell Culture Market, by Product6.1 IntroductionTable 18 Market, by Product, 2020-2028 (USD Million)6.2 Consumables6.2.1 Sera, Media, and Reagents6.2.2 Vessels6.2.3 Accessories6.3 Equipment6.3.1 Supporting Equipment6.3.2 Bioreactors6.3.3 Storage Equipment

7 Cell Culture Market, by Application7.1 IntroductionTable 277 Market, by Application, 2020-2028 (USD Million)7.2 Biopharmaceutical Production7.2.1 Monoclonal Antibody Production7.2.2 Vaccine Production7.2.3 Other Therapeutic Protein Production7.3 Diagnostics7.4 Drug Screening & Development7.5 Tissue Engineering & Regenerative Medicine7.5.1 Cell & Gene Therapy7.5.2 Other Tissue Engineering & Regenerative Medicine Applications7.6 Other Applications

8 Cell Culture Market, by End-user8.1 IntroductionTable 330 Cell Culture Market, by End-user, 2020-2028 (USD Million)8.2 Pharmaceutical & Biotechnology Companies8.3 Hospitals & Diagnostic Laboratories8.4 Research & Academic Institutes8.5 Other End-users

9 Cell Culture Market, by Region

10 Competitive Landscape

11 Company Profiles

12 Appendix12.1 Discussion Guide12.2 Knowledgestore: The Subscription Portal12.3 Customization Options

Companies Mentioned

Thermo Fisher Scientific Inc. (US)

Merck KGaA (Germany)

Danaher Corporation (US)

Corning Incorporated (US)

Eppendorf AG (Germany)

FUJIFILM Irvine Scientific, Inc. (Japan)

Lonza Group AG (Switzerland)

Sartorius AG (Germany)

Agilent Technologies, Inc. (US)

Getinge AB (Sweden)

Becton, Dickinson and Company (US)

Miltenyi Biotec (Germany)

HiMedia Laboratories (India)

STEMCELL Technologies Inc. (Canada)

Solida Biotech GmbH (Germany)

Caisson Laboratories Inc. (US)

PromoCell GmbH (Germany)

InvivoGen (US)

Pan-Biotech GmbH (Germany)

Cellexus (UK)

Meissner Filtration Products Inc. (US)

Adolf Kuhner AG (Switzerland)

SeraCare Life Sciences Inc. (US)

ANGUS Chemical Company (US)

Biospherix Ltd. (US)

For more information about this report visit https://www.researchandmarkets.com/r/vej4w1

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

Link:
Global Cell Culture Market Report 2023: Government Support and Funding for Cell-Based Research Bolsters Growth - Yahoo Eurosport UK

The Most Lasting Damage of the Bush Era Was Not the Iraq War – The New Republic

I have no doubt theres a few dissertations worth ofargument about exactly why political consensus around the war and consensusaround bodily autonomy had such disparate trajectories. Ultimately, it justseems like stories about dead soldiers and the constantly shifting foreignpolicy objectives that doomed them have an effect that stories about desperatewomen and an advancing medical dystopia dont.

For fans of American military bluster, the fantasy of theIraq adventure ran up against the reality of broken bodies and wasted billions a few years into the project, spelled out by the media with a remarkable lackof self-awareness and institutional memory. Democrats quickly and Republicanswith less haste recognized over time the human and material cost of theirdecision and changed their position accordingly.

Thats just not how its gone with the hellscape created byshrinking access to reproductive care. Im sure thats in part because the catastrophehas happened in ways and to people that allowed potentially persuadableRepublicans and, lets face it, most Democrats and the chattering class to ignoreit. Roe fell in America not with the Dobbs decision but instages, beginning with the most vulnerable Americans, until the curtain finallyfell on everyone else.

Visit link:
The Most Lasting Damage of the Bush Era Was Not the Iraq War - The New Republic